Current cardiology reports · 2026
Bioresorbable Scaffolds: Ready for a Rematch?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akinmolayemi Oludamilola, Levy Alexander, Patnaik Swagata, Stone Gregg W, Bienstock Solomon W
Аннотация
PURPOSE OF REVIEW: The bioresorbable vascular scaffold (BVS) is a promising technology with clear theoretical benefits. Large randomized controlled trials (RCTs) of the early generation of this technology, however, demonstrated issues translating these benefits from the abstract into the clinical realm. This review covers the outcomes beginning with the first-generation scaffolds and provides updates on advances made with newer technologies and evolved approaches to platform delivery.
RECENT FINDINGS: Pooled individual patient data from the ABSORB studies with 5-year follow-up was published in early 2025, showing higher event rates in the BVS group driven by events in the first three years of follow-up. Events after three years were the same or lower compared to traditional metallic drug-eluting stents (DES). BVS technology is not yet ready for clinical primetime. However, there is need for improved scaffold technology and new BVS will again need to be tested against metallic DES in large-scale RCTs with long-term follow-up.
RECENT FINDINGS: Pooled individual patient data from the ABSORB studies with 5-year follow-up was published in early 2025, showing higher event rates in the BVS group driven by events in the first three years of follow-up. Events after three years were the same or lower compared to traditional metallic drug-eluting stents (DES). BVS technology is not yet ready for clinical primetime. However, there is need for improved scaffold technology and new BVS will again need to be tested against metallic DES in large-scale RCTs with long-term follow-up.